Caris Life Sciences and National Cancer Center Japan Announce Exclusive Collaboration to Launch The SCRUM-Japan MONSTAR-SCREEN-2 Trial biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Session Time: April 13, 11:17-11:39 a.m. EST
Summary: Kaelin will highlight the important physiologic constraints a cancer tissue must operate within, focusing on the critical role hypoxia plays in not only tumor growth but progression, and how modulating the hypoxia machinery will limit tumor progression. The ability to target cancer at several molecular levels provides hope that our therapies will not only be more effective but also more durable. The lingering question is how to deploy these approaches by identifying which patients are most likely to benefit.
In addition to the exciting research presentations, Andrew Aguirre, MD, PhD, of the Dana-Farber Center for Gastrointestinal Oncology, has been named a 2021 AACR NextGen Star. Aguirre will present during the NextGen Stars Spotlight Session: Genetics and Epigenetics.
Share this article
Share this article
HOUSTON, March 4, 2021 /PRNewswire/ DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the treatment of the first patient in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand encoding oncolytic adenovirus, in patients with resectable liver metastasis. Expression of OX40 ligand on the surface of tumor cells is expected to enhance anti-tumor immune responses by providing costimulatory signals to T cells within the tumor microenvironment. We are excited to clinically explore the potential of one of our immunotherapy drug candidates, which is based on our proprietary adenovirus platform technology, in additional cancer indications, said Jeffrey Knapp, chief executive officer of DNAtrix. Our preclinical work with DNX-2440 has demonstrated that infection of human tumor cell lines with this agent leads to viral replication, high level expression of OX40 ligand on tumor cell
CELLS CONFIRMS THE ROLE OF MASITINIB AS A POTENTIAL THERAPY IN PANCREATIC CANCER
IDENTIFICATION OF TWO TISSUE BIOMARKERS THAT COULD POTENTIALLY SERVE AS PREDICTIVE BIOMARKERS OF RESPONSE FOR MASITINIB TREATMENT
Paris, 23 February 2021, 8am CET
AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of a peer-reviewed research article in which the authors conclude that inhibition of mast cells with masitinib could represent a novel antiangiogenetic approach in pancreatic cancer (antiangiogenic therapies reduce the growth of new blood vessels needed by tumors to grow and metastasize). The article, entitled ‘Mast Cells Positive for c‐Kit Receptor and Tryptase Correlate with Angiogenesis in Cancerous and Adjacent Normal Pancreatic Tissue , [1] is freely accessible online from the Cells journal site
Press release content from Business Wire. The AP news staff was not involved in its creation.
NOXXON Appoints Leading Pancreatic Cancer Experts to Scientific Advisory Board
February 8, 2021 GMT
Regulatory News:
NOXXON Pharma N.V.
(Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the appointment of four leading pancreatic cancer experts to its Scientific Advisory Board (SAB). Led by the newly appointed Chair, Dr. Jose Saro, the SAB will provide strategic and scientific counsel to NOXXON’s clinical programs in this indication.
“These prominent research leaders bring long-standing clinical expertise, cutting-edge scientific knowledge, and a track record of successfully developing new drugs to treat this devastating disease. They fully understand the challenges of developing new drugs for pancreas cancer where the tumor microenvironment plays a large role in resisting ant